Intimation of investor presentation under regulation 30 of SEBI (LODR) Regulations, 2015

21/08/2026 The Deputy Manager Corporate Relationship Department BSE Limited P. J. Towers, Dalal Street, Mumbai – 400001 Scrip Code: 544529 ISIN: INE15XJ01010 Dear Sir/Madam, Sub: Intimation of Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Please find enclosed herewith the investor presentation on financial results of the Company for the year ended 31st March, 2026. The presentation is also being uploaded on the website of the company i.e. www.aptus-pharma.com You are requested to kindly take the above information on your records. Thanking you, Yours faithfully For Aptus Pharma Limited Tejash Maheshchandra Hathi Managing Director DIN: 03151221 Encl.: Investor Presentation INVESTOR PRESENTATION We Deliver Quality & Innovation to Redefine Human Lives This communication is being issued by Aptus Pharma ltd.("the Company") for general information purposes only. The information contained herein is based on management's current expectations and beliefs and is subject to change without notice. Certain statements in this document may be forward-looking in nature and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements of the Company to differ materially from those expressed or implied. This document does not constitute or form part of any offer, invitation, or recommendation to purchase, hold, or sell any securities of the Company, nor shall any part of it form the basis of or be relied upon in connection with any contract or investment decision. The financial results referred to herein are prepared in accordance with applicable Indian Accounting Standards and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and are subject to audit / limited review by the statutory auditors of the Company. Neither the Company nor its directors, officers, employees, or advisors accept any liability whatsoever for any loss or damage arising from the use of this information. The Company undertakes no obligation to update any forward-looking statements or information contained herein to reflect subsequent events or circumstances, except as required under applicable law. Leader vision At Aptus Pharma Limited, our vision is to build a future where quality healthcare solutions are accessible, reliable, and driven by innovation. We aspire to be a globally trusted pharmaceutical organization, recognized for excellence, integrity, and sustainable growth. Our focus is on continuously strengthening our capabilities, embracing innovation, and setting new benchmarks in pharmaceutical excellence. Through a commitment to quality and responsible progress, we aim to create lasting value for patients, healthcare professionals, partners, and communities. With a future-oriented mindset, we are dedicated to shaping a healthier tomorrow—where growth is aligned with purpose, progress is guided by responsibility, and success is measured by the positive impact we create. Mr. Tejash Hathi Managing Director Driven by purpose. Defined by quality. Focused on the future. Key USPs of APPL Diversified portfolio across pharma, OTC, wellness, and personal care categories positions Aptus Pharma Limited as a dynamic and growth-oriented healthcare company. Aptus Pharma Limited operates an asset-light, marketing- and distribution-focused business model. Through outsourcing and loan licensing arrangements with WHO-GMP-certified contract manufacturers, the company conserves capital by avoiding heavy investments in manufacturing facilities. This strategic approach allows Aptus Pharma to redirect resources toward sales growth, brand building, product portfolio expansion, and the development of a strong nationwide supply chain. Table of Contents Company Overview Industry Overview Business Overview Financial Performance Way Ahead Thank You Company Overview Aptus Pharma Ltd., established in 2010, is a fast-growing player in India's pharmaceutical sector, driven by a strong focus on brand building and market expansion. The company is engaged in developing and promoting high-quality pharmaceutical brands across diverse therapeutic segments, earning trust among healthcare professionals and consumers. Operating on an asset-light model, Aptus partners with WHO-GMP certified manufacturers to ensure quality, scalability, and efficiency, enabling agile growth in competitive markets. With a growing presence across multiple states, the company has built a robust network of doctors, distributors, and healthcare professionals, supported by a dedicated field force. Aptus offers a diversified portfolio of 250+ formulations spanning chronic, acute, and wellness segments. Its business is strategically structured across key verticals: the Phrama Formulation Vertical, which drives core revenues through prescription-based therapies and strong doctor engagement; the OTC Vertical, focused on consumer healthcare and wellness products; and the Global Vertical, which expands international reach while contributing to revenue through exports and related service income. As a Public Limited Company listed on the BSE SME platform, Aptus Pharma Ltd. continues to strengthen its position with a vision of delivering accessible, affordable, and high-quality healthcare solutions while driving sustainable and scalable growth Core Values Core Purpose BRAND We Deliver PROMISE Quality & "We committed to healthcare Innovation and healthcare professionals." Aptus Pharma pledges to To Redefine uphold the highest standards in contributing to the well-being Human Lives of individuals and supporting the healthcare community. BUSINESS OVERVIEW 25,000+ Business Structure & Verticals Retailers 250+ Pharma Formulation Formulations across The Pharma Formulation vertical will remain a core revenue-generating business of Aptus Pharma. The business model is primarily focused on multiple therapies promoting branded generic formulations through a strong medical and sales network. Revenue generates through prescription generation by promoting branded generic products to doctors. 200+ Distributors The major therapeutic focus will be divided into: Acute - Chronic target therapies Acute therapies – products for short-term and immediate treatment requirements. 10,000+ Chronic therapies – products for long-term conditions requiring continuous treatment and repeat prescriptions. Doctor relationships supporting prescription generation The objective is to build strong brands, increase doctor coverage, expand the product portfolio and strengthen prescription-driven revenue across existing and new markets. 150+ Consumer Products Industry Professionals The Consumer Products vertical will focus on developing Aptus as a consumer healthcare, wellness and personal-care brand. Revenue will be generated by promoting OTC, wellness, personal-care and self-care products directly through traditional trade channels and, progressively, through a proposed e-commerce/D2C platform. Therapeutic Segments The key product categories will include: Skin Care, Face Care, Hair Care, Personal Hygiene, Wellness Products Self-Care OTC Products 50,000+ Prescriptions Per Day The strategy will be to build consumer-facing brands with repeat purchases and wider retail penetration, while using e-commerce to reach customers directly across India. Loan Licence Manufacturing Facility International Market & Export Services in Gujarat The International Business vertical will initially generate revenue through domestic merchant exporters and export-related services. facilitate international business by connecting overseas opportunities with associated manufacturing partners and generating service income Contract Manufacturing Agreements from business provided to associated manufacturers or exporters. NABL Accredited Associate Lab Journey / Key Milestones 2010 2011–2016 2016–2020 2021–2025 2025 - 2026 Incorporation of Aptus Early Growth Phase Por [Showing first 8,000 characters — download PDF for full document]